News | November 08, 2010

Report Gives New Insights for Improving Cardiac Care

November 8, 2010 – The American College of Cardiology (ACC) and American Heart Association (AHA) issued a joint report outlining new performance measures in cardiac care. The full report will be published in the Nov. 16 issue of the Journal of the American College of Cardiology.

“As performance measures have grown in importance, we must constantly be sure that they are created in the most sound scientific manner so that the goal of using these measures – to improve care – are most likely to be achieved,” said John A Spertus, M.D., MPH Daniel Lauer/Missouri Endowed Chair and professor, University of Missouri Kansas City and chair of the 12-person writing committee. “This document provides guidance to the creators of performance measures so that they can create the most useful measures to improve the quality of care.”

The inherent delay between the collection of new evidence and its adoption into routine care means performance measures do not always take emerging evidence into account. The updated report addresses this issue and ensures that only the processes of care associated with the strongest evidence and meaningful outcomes are endorsed, Spertus said.

“Professional societies have learned a lot about new challenges and opportunities since the original recommendations for the methodology of performance measure development were written five years ago,” he said. “Since performance measures, once developed, almost always become mandatory clinical actions, it is very important that the issues raised in this paper be considered so that adverse consequences can be avoided.”

Currently, performance measures are more often used as tools for accountability and reimbursement. Initially, they were intended to help physicians improve the quality of care and patient outcomes.

“As we use performance measures, we have learned how to make them more accurate, meaningful and actionable,” Spertus said. “Recently, insurers are starting to pay more for practices that more often comply with performance measures and major payers, such as Medicare, are increasingly publishing providers’ performance for the public to review.”

For more information: www.cardiosource.org

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init